ArticleEuropean journal of medical research2025
METTL3 inhibits osteoporosis by promoting osteoblast differentiation through m6A-mediated activation of the FZD3/RUNX1 signaling axis.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoporosis (OP) is a well-known metabolic bone disorder. This paper was to unveil the mechanism of the m6A methylation transferase METTL3 in OP.
methodsThrough literature search and sample analysis, m6A methylation transferase METTL3 was selected as the study object. Ovariectomy (OVX) was leveraged to build a mouse model of OP. The OVX mouse model was evaluated by RT-qPCR, Western blot, and HE staining. The oe-METTL3 or FZD3 lentiviral vectors were delivered into MC3T3-E1 cells and BMMs or injected intraperitoneally into OVX mice to observe the differentiation levels of osteoblasts and osteoclasts, as well as alterations in OP symptoms. Quantitative m6A analysis and RIP assays were performed to verify the downstream gene FZD3 of METTL3, and pathway enrichment was performed to analyze the signaling pathways regulated by FZD3. Rescue experiments were performed to verify the role of METTL3 on osteoblast and osteoclast differentiation through the FZD3/RUNX1 axis.
resultsMETTL3 and FZD3 were downregulated in osteoporotic mice. Overexpression of METTL3 or FZD3 in OVX mice promoted osteoblasts and osteogenesis and blocked osteoclast differentiation and bone resorption. METTL3 regulates FZD3 expression via m6A modification. FZD3 promoted osteoblast differentiation and bone formation while inhibiting osteoclast differentiation and bone resorption by regulating RUNX1, a protein downstream of the Wnt pathway. Overexpression of FZD3 partially reversed the effect of sh-METTL3 on osteoblast formation and osteoclast differentiation.
conclusionIn mouse and cell models, METTL3 promotes FZD3 expression through m6A modification, activates RUNX1 downstream of the Wnt pathway, stimulates osteoblast formation, prevents osteoclast differentiation, and thereby mitigates osteoporosis-like phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.